MARKET

AMRN

AMRN

Amarin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.401
-0.029
-2.05%
Opening 10:40 05/27 EDT
OPEN
1.410
PREV CLOSE
1.430
HIGH
1.460
LOW
1.360
VOLUME
617.12K
TURNOVER
543.81K
52 WEEK HIGH
5.97
52 WEEK LOW
1.110
MARKET CAP
556.09M
P/E (TTM)
-24.0257
1D
5D
1M
3M
1Y
5Y
BRIEF-HLS Therapeutics Obtains Public Reimbursement For Vascepa In Quebec
reuters.com · 3d ago
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has successfully entered into a Product Listing Agreement ("PLA") with the Quebec Minister ...
CNW Group · 3d ago
BRIEF-Amarin Announces Appointment Of New Directors And Board Leadership Changes
reuters.com · 05/19 13:49
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Ac...
GlobeNewswire · 05/19 12:23
Amarin Names Per Wold-Olsen Chairman
MT Newswires · 05/19 10:21
Looking Into Amarin Corp's Return On Capital Employed
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million.
Benzinga · 05/16 14:02
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two post...
GlobeNewswire · 05/16 12:00
Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences: H.C. Wainwri...
GlobeNewswire · 05/12 12:00
More
No Data
Learn about the latest financial forecast of AMRN. Analyze the recent business situations of Amarin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
37.50%Buy
37.50%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average AMRN stock price target is 3.607 with a high estimate of 9.00 and a low estimate of 1.500.
High9.00
Average3.607
Low1.500
Current 1.405
EPS
Actual
Estimate
-0.05-0.03-0.000.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 425
Institutional Holdings: 189.39M
% Owned: 47.70%
Shares Outstanding: 397.01M
TypeInstitutionsShares
Increased
52
20.68M
New
44
5.96M
Decreased
62
6.58M
Sold Out
37
3.91M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.04%
Pharmaceuticals & Medical Research
+0.41%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Karim Mikhail
Chief Financial Officer/Senior Vice President/Assistant Secretary
Michael Kalb
Senior Vice President/Chief Scientific Officer
Stephen Ketchum
Senior Vice President
Aaron Berg
Director
Per Wold-Olsen
Non-Executive Independent Director
Patrick O'Sullivan
Non-Executive Independent Director
Kristine Peterson
Non-Executive Independent Director
David Stack
Non-Executive Independent Director
Jan van Heek
Non-Executive Independent Director
Joseph Zakrzewski
No Data
No Data
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Webull offers kinds of Amarin Corporation plc (ADR) stock information, including NASDAQ:AMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRN stock methods without spending real money on the virtual paper trading platform.